Outcomes with FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer

BACKGROUND: Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer. METHODS: Retrospective review of outcomes of patients with borderl...

Full description

Saved in:
Bibliographic Details
Main Authors: Boone, Brian A., Steve, Jennifer, Krasinskas, Alyssa M., Zureikat, Amer H., Lembersky, Barry C., Gibson, Michael K., Stoller, Ronald, Zeh, Herbert J., Bahary, Nathan
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3816713/
https://ncbi.nlm.nih.gov/pubmed/23955427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.23392
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items